TransCode Therapeutics Awarded 2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
| RNAZ Stock | USD 3.35 0.94 21.91% |
Slightly above 61% of Transcode Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Transcode Therapeutics suggests that many traders are alarmed. Transcode Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Transcode Therapeutics' earnings reports, geopolitical events, and overall market trends.
Transcode |
Grant awarded by the National Cancer Institute of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138BOSTON, Sept. 05, 2024 -- TransCode Therapeutics, Inc. , the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a 2 million Direct to Phase II Small Business Innovation Research grant from the National Institutes of Health to support clin
Read at finance.yahoo.com
 |
Transcode Therapeutics Fundamental Analysis
We analyze Transcode Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash And Equivalents
Cash And Equivalents Comparative Analysis
Transcode Therapeutics is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Transcode Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Transcode Therapeutics stock to make a market-neutral strategy. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics with similar companies.
Peers
Transcode Therapeutics Related Equities
| EYEN | Eyenovia | 16.56 | ||||
| KOD | Kodiak Sciences | 7.81 | ||||
| RVPHW | Reviva Pharmaceuticals | 7.69 | ||||
| PHIO | Phio Pharmaceuticals | 1.36 | ||||
| SONN | Sonnet Biotherapeutics | 1.33 | ||||
| IMMX | Immix Biopharma | 0.61 | ||||
| XBIO | Xenetic Biosciences | 1.26 | ||||
| ZURA | Zura Bio | 3.76 | ||||
| CGTX | Cognition Therapeutics | 3.85 | ||||
| REVB | Revelation Biosciences | 5.01 | ||||
| ZVSA | ZyVersa Therapeutics | 8.20 | ||||
| CNSP | Cns Pharmaceuticals | 17.71 |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.